menu
    • menu
    [{"orgOrder":0,"company":"Jacobus Pharmaceutical Company, Inc","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Diaminopyridine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Jacobus Pharmaceutical Company, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jacobus Pharmaceutical Company, Inc \/ Jacobus Pharmaceutical Company, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Jacobus Pharmaceutical Company, Inc \/ Jacobus Pharmaceutical Company, Inc"},{"orgOrder":0,"company":"Jacobus Pharmaceutical Company, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Amifampridine","moa":"Voltage-gated potassium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Jacobus Pharmaceutical Company, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobus Pharmaceutical Company, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jacobus Pharmaceutical Company, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Jacobus Pharmaceutical Company, Inc","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amifampridine","moa":"Potassium voltage-gated channel subfamily A member 1||Voltage-gated potassium channel","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Jacobus Pharmaceutical Company, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobus Pharmaceutical Company, Inc \/ Jacobus Pharmaceutical Company, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Jacobus Pharmaceutical Company, Inc \/ Jacobus Pharmaceutical Company, Inc"},{"orgOrder":0,"company":"Jacobus Pharmaceutical Company, Inc","sponsor":"MEDUNIK CANADA","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"Voltage-gated potassium channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jacobus Pharmaceutical Company, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jacobus Pharmaceutical Company, Inc \/ Jacobus Pharmaceutical Company, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Jacobus Pharmaceutical Company, Inc \/ Jacobus Pharmaceutical Company, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Jacobus Pharmaceutical Company, Inc

    Menu

    Jacobus Pharmaceutical Company, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amifampridine Phosphate

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Recipient : MEDUNIK CANADA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Médunik Canada's Ruzurgi® Now Available to Canadian Lambert-Eaton Myasthenic Syndrome Patients

                            Details : Médunik Canada has retained the services of Innomar, a leading specialty pharmaceutical service and patient support program provider, for the distribution of Ruzurgi® and management of its UnikAccess Patient Support Program.

                            Product Name : Ruzurgi

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 25, 2020

                            Lead Product(s) : Amifampridine Phosphate

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Recipient : MEDUNIK CANADA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Jeffrey A. Cohen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

                            Details : 3,4-Diaminopyridine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscle Weakness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2014

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Jeffrey A. Cohen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diaminopyridine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Recipient : Oregon Health and Science University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

                            Details : Diaminopyridine is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Lambert-Eaton Myasthenic Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 17, 2013

                            Lead Product(s) : Diaminopyridine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Recipient : Oregon Health and Science University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jacobus Pharmaceutical Company, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

                            Details : 3,4-DAP is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lambert-Eaton Myasthenic Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2012

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth